Kostas Tzelepis

This account is verified. Learn more

@TzelepisLab

Wellcome Trust Investigator @Cambridge_Uni. New RNA biology. Discovery of novel epitranscriptomic targets and treatments. Bench-to-clinic research.

University of Cambridge, UK stemcells.cam.ac.uk/people/pi/tzel… Joined August 2020

752 Following 1.1K Followers 695 Posts

Latest posts 5

Pinned post

Kostas Tzelepis @TzelepisLab Apr 26, 2021

Very proud to announce our latest paper @nature showing the development and characterisation of the first-in-class catalytic inhibitor of METTL3 against AML. A superb collaboration between our lab (@TheMilnerInst, @sangerinstitute), @storm_tx and @TKLABUK
disq.us/t/3wgxg9e

Kostas Tzelepis @TzelepisLab 4d

Grateful to have @itvnews and @itvanglia covering our recent study at @SCICambridge and @Cambridge_Uni!!

ITV News Anglia @itvanglia 5d

Scientists working on a ten-year research project hope their work can boost survival rates for patients with the aggressive cancer.

itv.com/watch/news/sci…

View quoted post on X

Kostas Tzelepis @TzelepisLab Oct 28

Today in @Nature we present the development and characterisation of the first-in-class catalytic inhibitor of METTL1 as a new therapeutic strategy against solid and blood cancers.

Another flagship collaboration between my lab @SCICambridge @Cambridge_Haem (@Cambridge_Uni) and @storm_tx, co-led by my brilliant colleague @OliverRausch and driven by Eliza Yankova, Alexandra Sapetschnig and Beth Thomas.

A big thank you to the long list of authors who participated in this study and provided their critical input and diverse expertise. I am also very thankful and lucky to have the continuous support of @wellcometrust, @LeukUK and @CR_UK.

nature.com/articles/s4158…

www.nature.com Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers Nature - Pharmacological inhibition of the m7G methyltransferase METTL1 in vivo impairs tumour growth and substantially prolongs survival in multiple mouse cancer models of different tissue origin.

Kostas Tzelepis @TzelepisLab Sep 29

Today in @NatRevDrugDisc (#NRDD), we proudly present a timely Perspective on the overall druggable landscape of RNA-binding proteins (RBPs), with a strong emphasis on the recent and exciting scientific advances around cell surface RBPs (csRBPs) in disease.

Many congratulations and a big thank you to my absolutely amazing colleague @GaiaTimote98110 for putting this inspiring piece together, as well as to my fantastic collaborators and key experts in the field, @AbdelWahablab, Ryan Flynn, and Benson George for their very important contributions!

We hope that our Perspective will benefit the wider scientific community by providing a clearer understanding of the therapeutic potential of targeting RBPs and csRBPs.
nature.com/articles/s4157…

www.nature.com The cellular landscape of druggable RNA-binding proteins Nature Reviews Drug Discovery - RNA-binding proteins (RBPs) regulate every step of cellular RNA metabolism, and their dysregulation contributes to many diseases. This Perspective describes the...

Kostas Tzelepis @TzelepisLab Aug 8

Today in @NatureComms we present the identification and characterisation of the NAT10 helicase domain as a novel therapeutic target for cancer. A fantastic collaboration with Daniel Arango and his amazing lab at @NorthwesternU🔥🔥

I am very grateful to all the scientists that contributed to this exciting study! Special thanks to @wellcometrust , @CR_UK and @LeukUK for supporting our work here at the @SCICambridge, @Cambridge_Uni!!
nature.com/articles/s4146…

www.nature.com The RNA helicase domain of NAT10 promotes the biogenesis of hypomodified ribosomes to enhance... Nature Communications - The mechanisms underlying the role of N-acetyltransferase 10 (NAT10) in cancer remain poorly characterised. Here, PROTAC-mediated degradation of NAT10 with a deep mutational...